Current Report Filing (8-k)
August 24 2022 - 6:03AM
Edgar (US Regulatory)
0001419554
false
0001419554
2022-08-23
2022-08-23
0001419554
BBLG:CommonStock0.001ParValuePerShareMember
2022-08-23
2022-08-23
0001419554
BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember
2022-08-23
2022-08-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 23, 2022
BONE
BIOLOGICS CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware |
|
000-53078 |
|
42-1743430 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
2
Burlington Woods Drive, Ste. 100
Burlington,
MA |
|
01803 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781) 552-4452
Securities
registered pursuant to section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, $0.001 par value per share |
|
BBLG |
|
The
Nasdaq Stock Market LLC |
|
|
|
|
|
Warrants
to Purchase Common stock, $0.001 par value per share |
|
BBLGW |
|
The
Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
Annual
Meeting of Stockholders
An
annual meeting (“Annual Meeting”) of the stockholders of Bone Biologics Corporation, a Delaware corporation (the “Company”),
was held on August 23, 2022. The Company filed its definitive proxy statement in connection with the Annual Meeting with the Securities
and Exchange Commission on July 6, 2022 (which can be viewed at: www.sec.gov). The Company’s stockholders considered the following
proposals at the Annual Meeting:
● |
Proposal
I: A proposal to elect Don Hankey, Stephen La Neve, Bruce Stroever, Erick Lucera and Siddhesh Angle to the Company’s Board
of Directors; and |
|
|
● |
Proposal
II: A proposal to approve on an advisory basis the compensation of the Company’s named executive officers; and |
|
|
● |
Proposal
III: A proposal to ratify the appointment of Weinberg & Company, P.A., as our independent registered public accountant for the
fiscal year ending December 31, 2022. |
Voting
Results
Proposal
I: The election of the directors was approved as follows:
|
|
FOR |
|
WITHHELD |
|
BROKER
NON-VOTES |
|
|
|
|
|
|
|
Don
Hankey |
|
7,301,750 |
|
10,154 |
|
666,720 |
|
|
|
|
|
|
|
Stephen
La Neve |
|
7,301,650 |
|
10,254 |
|
666,720 |
|
|
|
|
|
|
|
Bruce
Stroever |
|
7,299,542 |
|
12,362 |
|
666,720 |
|
|
|
|
|
|
|
Erick
Lucera |
|
7,300,254 |
|
11,650 |
|
666,720 |
|
|
|
|
|
|
|
Siddhesh
Angle |
|
7,266,793 |
|
45,111 |
|
666,720 |
Proposal
II: Approval of Executive Compensation was approved with 7,271,303 “FOR” votes, 29,002 “AGAINST” votes, 11,599
“ABSTAIN” votes and 666,720 broker non-votes.
Proposal
III: Ratification of the appointment of Weinberg & Company, P.A., as independent registered public accountant for the fiscal year
ending December 31, 2022 was approved with 7,965,696 “FOR” votes, 1,274 “AGAINST” votes and 11,654 “ABSTAIN”
votes.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Date:
August 23, 2022 |
Bone
Biologics Corporation |
|
|
|
|
By: |
/s/
JEFFREY FRELICK |
|
Name: |
Jeffrey
Frelick |
|
Title: |
Chief
Executive Officer |
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bone Biologics (NASDAQ:BBLG)
Historical Stock Chart
From Sep 2023 to Sep 2024